79 related articles for article (PubMed ID: 7074598)
1. Toxicity and pharmacokinetics of a new antifolate, 2,4-diamino-5-adamantyl-6-methylpyrimidine, in dogs.
Zakrzewski SF; Pavelic Z; Greco WR; Bullard G; Creaven PJ; Mihich E
Cancer Res; 1982 Jun; 42(6):2177-83. PubMed ID: 7074598
[TBL] [Abstract][Full Text] [Related]
2. Studies with a new antifolate 2,4-diamino-5-adamantyl-6-methylpyrimidine (DAMP): tissue distribution and disposition of 2,4-diamino-5-adamantyl-6-methylpyrimidine and its metabolite.
Zakrzewski SF; Dave C; Mead LH; Deluomo DS
J Pharmacol Exp Ther; 1978 Apr; 205(1):19-26. PubMed ID: 633083
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and toxicity of a potent "nonclassical" 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs.
Weir EC; Cashmore AR; Dreyer RN; Graham ML; Hsiao N; Moroson BA; Sawicki WL; Bertino JR
Cancer Res; 1982 May; 42(5):1696-702. PubMed ID: 6461409
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the antitumor activity and toxicity of 2,4-diamino-5-(1-adamantyl)-6-methylpyrimidine and 2,4-diamino-5-(1-adamantyl)-6-ethylpyrimidine.
Zakrzewski SF; Dave C; Rosen F
J Natl Cancer Inst; 1978 May; 60(5):1029-33. PubMed ID: 580441
[TBL] [Abstract][Full Text] [Related]
5. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
6. Disposition and metabolism of finasteride in dogs.
Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
8. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
9. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and bioavailability of acyclovir in the dog.
Krasny HC; de Miranda P; Blum MR; Elion GB
J Pharmacol Exp Ther; 1981 Feb; 216(2):281-8. PubMed ID: 7463350
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone.
Prakash C; Kamel A; Anderson W; Howard H
Drug Metab Dispos; 1997 Feb; 25(2):206-18. PubMed ID: 9029052
[TBL] [Abstract][Full Text] [Related]
12. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.
Zhang X; Zhang R; Zhao H; Cai H; Gush KA; Kerr RG; Pettit GR; Kraft AS
Cancer Res; 1996 Feb; 56(4):802-8. PubMed ID: 8631017
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and excretion of ropivacaine in humans.
Halldin MM; Bredberg E; Angelin B; Arvidsson T; Askemark Y; Elofsson S; Widman M
Drug Metab Dispos; 1996 Sep; 24(9):962-8. PubMed ID: 8886605
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of triclopyr (3,5,6-trichloro-2-pyridinyloxyacetic acid) in the beagle dog and rhesus monkey: perspective on the reduced capacity of dogs to excrete this organic acid relative to the rat, monkey, and human.
Timchalk C; Nolan RJ
Toxicol Appl Pharmacol; 1997 Jun; 144(2):268-78. PubMed ID: 9194410
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics of genistein in beagle dogs].
Zhou SY; Mei QB; Yang XB; Li X; Hu YZ; Wang JB
Yao Xue Xue Bao; 2003 Sep; 38(9):646-9. PubMed ID: 14730910
[TBL] [Abstract][Full Text] [Related]
17. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
18. Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog.
Kaul S; Shyu WC; Shukla UA; Dandekar KA; Barbhaiya RH
Drug Metab Dispos; 1993; 21(3):447-53. PubMed ID: 8100500
[TBL] [Abstract][Full Text] [Related]
19. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
